nach oben

Erschienen in:

02.12.2019 | Research Article

Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([¹⁸F]FAMT) Uptake in Patients with Lung Cancer

verfasst von: Kimihiro Shimizu, Kyoichi Kaira, Tetsuya Higuchi, Takeshi Hisada, Takehiko Yokobori, Tetsunari Oyama, Takayuki Asao, Yoshito Tsushima, Ken Shirabe

Erschienen in: Molecular Imaging and Biology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

3-[¹⁸F]Fluoro-α-methyl-L-tyrosine ([¹⁸F]FAMT) is an amino acid positron emission tomography (PET) tracer specific for cancer detection by assessment of tumor amino acid metabolism. Little is known on whether or not the uptake of [¹⁸F]FAMT within cancer cells is associated with the expression of programmed death ligand-1 (PD-L1), a predictor of anti-PD-1 antibody efficacy. We conducted a clinicopathological study to assess the expression of PD-L1 and the presence of tumor-infiltrating lymphocytes (TILs) in patients with non-small cell lung cancer (NSCLC) diagnosed by PET.

Procedures

A total of 75 patients with NSCLC who underwent [¹⁸F]FAMT and 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) PET were enrolled in the study. Tumor specimens were stained by immunohistochemistry for glucose transporter 1 (Glut1), PD-L1 (using different antibody clones including E1L3N and 28-8), CD3, CD4, and CD8. The uptake of [¹⁸F]FAMT was correlated with clinicopathological variables.

Results

High uptake of [¹⁸F]FAMT was significantly associated with disease staging, initial treatment (surgical resection or chemotherapy), and the expression of PD-L1 (E1L3N). The value of the maximum standardized uptake value (SUV_max) for [¹⁸F]FAMT was significantly correlated with PD-L1 (E1L3N) expression, Glut1, and the SUV_max for [¹⁸F]FDG in patients with histological results of adenocarcinoma (AC) and advanced disease. A validation cohort for anti-PD-L1 using clone 28-8 showed a statistically significant correlation between SUV_max for [¹⁸F]FAMT and the expression of PD-L1 (28-8) and between the expression of PD-L1 (E1L3N) and PD-L1 (28-8).

Conclusions

The uptake of [¹⁸F]FAMT on PET imaging was significantly correlated with PD-L1 expression in NSCLC, especially in patients with AC and advanced disease.

Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 Study. J Clin Oncol 36:1675–1684CrossRef

Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE-189 Investigators (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092CrossRef

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L (2018) Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093–2104CrossRef

Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T (2018) Metabolic activity by ¹⁸F-FDG-PET/CT is predictive for early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging 45:56–66CrossRef

Kasahara N, Kaira K, Bao P et al (2018) Correlation of tumor-related immunity 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer 119:71–77CrossRef

Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, Ohtaki Y, Higuchi T, Oyama T, Asao T, Mogi A (2018) ¹⁸F-FDG uptake on PET is associated with PD-L1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer 101:181–190CrossRef

Seith F, Forschner A, Schmidt H, Pfannenberg C, Gückel B, Nikolaou K, la Fougère C, Garbe C, Schwenzer N (2018) 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. Eur J Nucl Med Mol Imaging 45:95–101CrossRef

Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, Yang D (1997) Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun 18:169–175CrossRef

10.

Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Endo K, Mori M (2007) Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 131:1019–1027CrossRef

11.

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M (2009) Evaluation of thoracic tumor with (18) F-FMT and (18) F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152–1160CrossRef

12.

Kaira K, Higuchi T, Sunaga N, Arisaka Y, Hisada T, Tominaga H, Oriuchi N, Asao T, Tsushima Y, Yamada M (2016) Usefulness of ¹⁸F-α-methyltyrosine PET as therapeutic monitoring of patients with advanced lung cancer. Anticancer Res 36:6481–6490CrossRef

13.

Kumasaka S, Nakajima T, Arisaka Y et al (2018) Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer. BMC Med Imaging 18:46CrossRef

14.

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K (2009) 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 50:1770–1776CrossRef

15.

Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Honda H, Oda Y, Maehara Y (2017) Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med 6:2552–2561CrossRef

16.

Zhang M, Wang D, Sun Q, Pu H, Wang Y, Zhao S, Wang Y, Zhang Q (2017) Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 8:51630–51640CrossRef

17.

Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753CrossRef

18.

Chen R, Zhou X, Liu J, Huang G (2019) Relationship between the expression of PD-1/PD-L1 and ¹⁸F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging 46:848–854CrossRef

19.

Chang YL, Yang CY, Lin MW, Wu CT, Yang PC (2016) High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer 60:125–135CrossRef

20.

Ruf M, Moch H, Schraml P (2016) PD-L1 expression is regulated by hypoxia inducible factor in clear renal cell carcinoma. Int J Cancer 139:396–403CrossRef

21.

Noman MZ, Desantis G, Janji B et al (2014) PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781–790CrossRef

22.

Chang CH, Qiu J, O’Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241CrossRef

23.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ (2016) Tumor-intrinsic PD-L1signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76:6964–6974CrossRef

24.

Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K, Mori M (2007) Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 13:6369–6378CrossRef

25.

Kaira K, Oriuchi N, Takahashi T et al (2011) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 3:468–478PubMedPubMedCentral

26.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222CrossRef

27.

Adam J, Le Stang N, Rouquette I et al (2018) Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 29:953–958CrossRef

Titel: Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer
verfasst von: Kimihiro Shimizu
Kyoichi Kaira
Tetsuya Higuchi
Takeshi Hisada
Takehiko Yokobori
Tetsunari Oyama
Takayuki Asao
Yoshito Tsushima
Ken Shirabe
Publikationsdatum: 02.12.2019
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 4/2020
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-019-01456-w

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([¹⁸F]FAMT) Uptake in Patients with Lung Cancer